DUBLIN–(BUSINESS WIRE)–Research and Markets (http://ift.tt/21helVx) has actually announced the addition of the “OpportunityAnalyzer: Acute Myeloid Leukemia (AML) – possibility Analysis and Projections to 2024” report to their offering.
The global Acute Myeloid Leukemia Promote will certainly reach a value of $932 thousand in 2024 at a CAGR of 10.5%.
Key Topics Covered:
- Overview of AML, consisting of epidemiology, etiology, pathophysiology, symptoms, diagnosis, and health problem management.
- Annualized AML therapeutics Promote revenue, expenditure of treatment each patient, and therapy consumption designs in 4 patient segments (including, young patients, elderly patients, refractory/relapsed patients and FLT3 mutated patients), forecast from 2014 to 2024.
- Key topics covered consist of strategic competitor assessment, Promote characterization, unmet needs, health care trial mapping and implications When it come to the AML therapeutics market.
- Pipeline analysis: comprehensive data analyzing emerging fads and mechanisms of action under improvement When it come to various lines of therapy. The the majority of promising candidate in Stage III improvement is profiled.
Benefits of this Report:
- Develop and make your in-licensing and out-licensing Plans with a review of pipeline product and services and technologies, and by recognizing the firms along with the the majority of robust pipeline.
- Develop Firm Plans by learning the fads shaping and driving the global AML therapeutics market.
- Drive revenues by learning the Essential trends, innovative product and services and technologies, Promote segments, and firms most likely to influence the global melanoma therapeutics Promote in the future.
- Formulate efficient sales and marketing Plans by learning the challenging landscape and by analysing the efficiency of numerous competitors.
Companies Mentioned:
- Actinium pharmaceuticals
- Agios pharmaceuticals
- Astellas Pharmaceuticals
- Ambit Biosciences
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celator Pharmaceuticals
- Celgene
- CTI BioPharma
- Cyclacel
- Daiichi Sankyo
- Eisai
- Epizyme
- Janssen-Cilag
- Novartis
- Merus
- MEI Pharma
- Otsuka Pharmaceuticals
- Pfizer
- Sanofi
- Seattle Genetics
- Stemline Therapeutics
- Sunesis
- Sumitomo Dainippon Pharma
- Synta Pharmaceuticals
Report Structure:
1.1 List of Tables
1.2 List of Figures
2 Introduction
3 health problem Overview
4 Epidemiology
5 health problem Management
6 Current therapy Options
7 Unmet calls for Assessment and possibility Analysis
8 R&D Strategies
9 Pipeline Assessment
10 Pipeline Valuation Analysis
11 Appendix
For much more short article head to http://ift.tt/21helVx
